JAK Inhibitors in Atopic Dermatitis: Advances in Treatment Care
JAK inhibitors in atopic dermatitis have transformed the treatment landscape for patients with moderate to severe disease, offering faster itch relief and more targeted immune modulation than many traditional therapies. Atopic dermatitis (AD), commonly known as eczema, is one of the most prevalent chronic inflammatory skin diseases in the world, affecting up to 20% of children and 10% of adults. Characterized by intense itch, skin barrier dysfunction, and recurrent flares of eczematous skin lesions, AD carries a substantial quality-of-life burden that includes sleep disruption, anxiety, depression, and difficulty at school and work. For patients with moderate to severe disease that cannot be controlled with topical therapies and emollients, systemic atopic dermatitis treatment options are now more sophisticated and more numerous than ever before, and at the center of this evolution is a class of medications known as Janus kinase (JAK) inhibitors.
Understanding the JAK-STAT Pathway in Atopic Dermatitis
JAK inhibitors in atopic dermatitis work by blocking the Janus kinase family of enzymes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are essential intermediaries in the signaling pathways of many pro-inflammatory cytokines. In atopic dermatitis, the JAK-STAT pathway is central to the pathology: cytokines, including IL-4, IL-13, IL-31, IL-22, TSLP, and others, bind to receptors on immune and skin cells, triggering JAK activation and downstream inflammatory cascades that cause itch, skin inflammation, and barrier disruption.
By selectively inhibiting JAK1 or broader combinations of JAK family members, JAK inhibitors interrupt these inflammatory signals at a fundamental level. The specificity of different JAK inhibitors matters: JAK1-selective agents like abrocitinib and upadacitinib are designed to target the most relevant inflammatory pathways in AD while minimizing off-target effects that could arise from more broadly inhibiting all JAK family members.
Oral JAK Inhibitors: Upadacitinib and Abrocitinib
Two oral JAK1-selective inhibitors are currently FDA-approved as new treatments for atopic dermatitis (moderate to severe) in adults and adolescents: upadacitinib (Rinvoq, AbbVie) and abrocitinib (Cibinqo, Pfizer).
Upadacitinib (15 mg or 30 mg once daily) has consistently demonstrated impressive clinical trial results. In the Measure Up 1 and Measure Up 2 phase 3 trials, both doses of upadacitinib produced statistically significant improvements in IGA scores and EASI-75 (a 75% reduction in eczema area and severity) compared to placebo in patients aged 12 and older with moderate to severe AD. Notably, upadacitinib demonstrated meaningful itch relief as early as one week into treatment – a particularly important outcome for patients whose quality of life is most severely affected by pruritus.
A 2025 network meta-analysis comparing biologics vs JAK inhibitors for pediatric AD found that upadacitinib 30 mg demonstrated the highest efficacy, with 62% more patients achieving clinical improvement compared to placebo. These findings continue to position JAK inhibitors among the most important advances in modern atopic dermatitis treatment.
Long-term extension data presented in 2025 showed that patients treated with upadacitinib 15 mg and 30 mg maintained EASI-75 and EASI-90 responses for more than 2.5 years, with consistent safety profiles, providing important reassurance that the drug’s efficacy is durable rather than transient.
Abrocitinib (100 mg or 200 mg once daily) has similarly demonstrated strong efficacy in the JADE MONO-1, JADE MONO-2, and JADE COMPARE phase 3 trials. The JADE COMPARE trial directly compared abrocitinib 200 mg against dupilumab, the benchmark biologic for AD, finding that abrocitinib provided significantly faster itch relief in the head-neck region. For patients who prioritize rapid symptom relief, particularly itch, abrocitinib may offer an advantage in speed of response when evaluating biologics vs JAK inhibitors. Real-world data from multicenter cohort studies continue to confirm the effectiveness of both agents, with mean reductions in disease severity scores of over 80% in many populations.
Topical JAK Inhibitors: Ruxolitinib and Delgocitinib
For patients with mild to moderate AD, or those who prefer to avoid systemic agents, topical JAK inhibitors in atopic dermatitis offer targeted anti-inflammatory activity without meaningful systemic absorption.
Ruxolitinib cream 1.5% (Opzelura, Incyte) is a topical JAK1/JAK2 inhibitor FDA-approved for mild to moderate AD in patients aged 12 and older. Phase 3 clinical trials demonstrated that ruxolitinib cream significantly outperformed vehicle in achieving IGA treatment success. In 2025, ruxolitinib cream 1.5% received expanded FDA approval for children aged 2 to 11 years, addressing a major unmet need in pediatric atopic dermatitis treatment/management. In clinical trials in this younger population, 56.5% of patients receiving ruxolitinib cream achieved IGA treatment success compared to just 10.8% with vehicle.
Delgocitinib (Anzupgo, LEO Pharma) is a pan-JAK inhibitor (targeting JAK1, JAK2, JAK3, and TYK2) approved for a distinct indication: moderate to severe chronic hand eczema in adults. Chronic hand eczema affects approximately 1 in 10 adults and had no FDA-approved targeted therapy until delgocitinib’s approval in 2025. The drug met co-primary endpoints in phase 3 trials and provides a genuinely novel option for this common and functionally limiting condition.
Safety Considerations with JAK Inhibitors
While JAK inhibitors in atopic dermatitis have become some of the most important new treatments for atopic dermatitis, they carry a class-related safety profile that requires attention and appropriate patient selection. The FDA requires boxed warnings for all systemic JAK inhibitors regarding risks of serious infections, malignancy (particularly lymphoma and non-melanoma skin cancer), major adverse cardiovascular events (MACE), thrombosis, and mortality, primarily derived from data in older patients with rheumatoid arthritis who were also cardiovascular risk factors.
For the younger, healthier population typically seeking atopic dermatitis treatment, the absolute risks are considerably lower, but monitoring is still important. Patients considering systemic JAK inhibitors should work closely with a qualified, board-certified dermatologist to evaluate their individual risk profile, treatment goals, and long-term management strategy.
Recommended pre-treatment screening includes baseline complete blood count with differential, liver enzymes, lipid panel, tuberculosis testing, viral hepatitis screening, and pregnancy test, where applicable. Shingles vaccination before initiation is recommended, and live vaccines should be completed prior to starting treatment. Regular laboratory monitoring during treatment is advised, with specific intervals varying by agent. Clinicians follow current AAD and FDA guidelines for monitoring to help ensure patient safety throughout treatment with JAK inhibitors in atopic dermatitis.
Topical ruxolitinib and delgocitinib have considerably lower systemic exposure than oral agents and carry a more limited safety profile, without the boxed warning requirements that apply to systemic JAK inhibitors. This makes them valuable new treatments for atopic dermatitis and appropriate options for patients who prefer topical treatment or for whom systemic immunosuppression poses greater risks.
Choosing Between JAK Inhibitors and Biologics
A common clinical question involves biologics vs JAK inhibitors for moderate to severe AD. JAK inhibitors are often compared with biologics such as dupilumab (Dupixent) and lebrikizumab (Ebglyss), both of which have become important options in modern atopic dermatitis treatment.
Network meta-analyses suggest that upadacitinib 30 mg may have higher efficacy than dupilumab for some clinical endpoints, though the biologic has a longer safety track record spanning over 7,000 patient-years across multiple phase 3 trials. Dupilumab also has a broader evidence base for comorbid conditions like asthma, allergic rhinitis, and chronic rhinosinusitis with nasal polyps, making it particularly attractive for patients with multiple atopic conditions.
JAK inhibitors may be preferred in patients who need rapid itch relief, those who have not responded to dupilumab, patients who prefer oral over injectable therapy, or individuals whose clinical profile makes a JAK inhibitor mechanistically well-suited. The expanding range of both topical and systemic options means that individualized decision-making, based on disease severity, patient age, comorbidities, prior therapy, patient preference, and insurance access, is increasingly possible and important.
Atopic Dermatitis Care at Trillium Clinic
Atopic dermatitis is more than a cosmetic nuisance; it is a systemic inflammatory condition with meaningful impact on mental health, sleep, relationships, and productivity. At Trillium Clinic, a trusted dermatology clinic near Chapel Hill, we take a comprehensive approach to AD management that begins with accurate diagnosis, skin care education, and trigger identification, and extends through stepwise escalation to advanced therapies, including both topical and systemic JAK inhibitors in atopic dermatitis and biologics when indicated.
Our team includes experienced specialists who provide personalized atopic dermatitis treatment and help patients navigate the nuances of JAK inhibitor therapy, including appropriate patient selection, pre-treatment workup, dosing decisions, and long-term monitoring. If you or your child is struggling with atopic dermatitis that has not responded adequately to moisturizers, topical steroids, or other conventional treatments, we encourage you to reach out. A consultation with one of our dermatologists can open the door to a more effective, individualized treatment plan.
FAQs
They are targeted medications that block inflammatory signaling pathways involved in eczema. By interrupting the JAK-STAT pathway, these treatments help reduce itching, inflammation, and skin barrier dysfunction associated with moderate to severe atopic dermatitis.
When evaluating biologics vs JAK inhibitors, both can be highly effective. JAK inhibitors often provide faster itch relief and are available as oral medications, while biologics have a longer-term safety record and may be particularly beneficial for patients with related allergic conditions such as asthma or chronic sinus disease.
Patients with moderate to severe eczema that has not responded adequately to moisturizers, topical steroids, or other conventional therapies may be candidates for JAK inhibitors. A dermatologist will evaluate disease severity, medical history, and potential risk factors before recommending treatment.
Clinical studies have demonstrated durable effectiveness with long-term use, but JAK inhibitors require appropriate monitoring. Depending on the medication, your dermatologist may recommend periodic blood work and screening tests to help ensure treatment remains safe and effective.
Yes. Ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and offers targeted anti-inflammatory activity with minimal systemic absorption. Topical JAK inhibitors may be a good option for patients who prefer to avoid oral medications.
